In The News
Full Court tosses ruling that Noumi waived privilege over PwC report
Johnson & Johnson hit with class action over cold and flu medications
‘In all circumstances unconscionable’: ASIC wins case against forex broker
Graincorp class action seeks to bring toxicity claims
Investor class action against Linchpin insurer AIG prevails
Judge approves $57.5M ANZ class action settlement, funder’s ATE costs
ACCC shuts lawyers for cartel immunity seekers out of the room
AGL cops a $25M penalty for overcharging welfare recipients
IC Markets CEO hit with guillotine orders for filing defence
Swoosh accused of providing credit to financially stressed customers
Please login to bookmarkClose

German drug company Fresenius Kadi has resolved a patent case brought by Korean drug company Samsung Bioepis over a biosimilar of top selling arthritis drug Humira.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au